secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001516551-22-000033
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 4.01, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye shareholders approve acquisition of Emerald Health; Phase 1 trial imminent
-------------------------------------------------------------------------------

- 97% of votes cast (excluding affiliates) approved the acquisition of Emerald Health Therapeutics.
- Expected closing before October 15, subject to Canadian Securities Exchange listing approval.
- Phase 1 trial of SBI-100 in glaucoma to start in Australia; first dosing expected in November 2022.
- Final manufacturing step is quality testing; drug product expected to be available in October 2022.
- Auditor changed from Friedman LLP to Marcum LLP following merger; no disagreements reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000033/0001516551-22-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655122000033/skye-20220929.htm
  HTML page:      https://secwatch.observer/filing/0001516551-22-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer